Compare HUIZ & RKTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HUIZ | RKTO |
|---|---|---|
| Founded | 2006 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.8M | 18.9M |
| IPO Year | 2019 | 2018 |
| Metric | HUIZ | RKTO |
|---|---|---|
| Price | $1.69 | $0.75 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.30 | N/A |
| AVG Volume (30 Days) | ★ 2.8M | 419.9K |
| Earning Date | 06-05-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.69 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.58 | N/A |
| Revenue Next Year | $6.64 | N/A |
| P/E Ratio | $7.81 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.04 | $0.70 |
| 52 Week High | $4.16 | $1.19 |
| Indicator | HUIZ | RKTO |
|---|---|---|
| Relative Strength Index (RSI) | 59.06 | 37.49 |
| Support Level | $1.33 | $0.70 |
| Resistance Level | $1.87 | $0.84 |
| Average True Range (ATR) | 0.39 | 0.04 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 25.00 | 20.39 |
Huize Holding Ltd is an independent online insurance product and service platform in China. The company distributes on its platform insurance products underwritten by the insurance companies that cooperate with the company, which the company refers to as its insurer partners, and helps them reach a large number of insurance clients. The company's platform offers a digitalized insurance purchase experience and services through various internet and mobile internet channels. The company generates revenues from the insurance brokerage fees paid by its insurer partners.
Rocket One Inc is focused on developing and commercializing infrastructure for the orbital economy, including next-generation nanomagnetic AI chip technology designed for radiation-tolerant, energy-constrained environments such as low-Earth orbit, deep-space platforms, and defense systems. The company also intends to pursue opportunities related to nano-launch systems and nanosatellite deployment. In addition, its biotechnology operations, conducted through a wholly owned subsidiary, include development programs such as HT-001, HT-KIT, HT-ALZ, and a GDNF-based metabolic program.